How Scientists Are Using Engineered Immune Cells to Fight HIV

Caring Cross announced early clinical results from a trial testing a new approach to HIV treatment: using patients' own immune cells, genetically modified to hunt down and destroy HIV-infected cells. The results, presented at the American Society of Gene and Cell Therapy conference in Boston, suggest this approach could allow some patients to go without daily antiviral medications—at least for extended periods.

The trial tested something called duoCAR-T therapy. Here's the basic idea: doctors extract T cells (a type of immune cell) from a patient's blood, use genetic engineering to reprogram them to recognize HIV-infected cells, and then reinfuse them back into the patient. It's a one-time treatment designed to let those engineered cells find and eliminate the virus on their own.

Early Results Show Promise

The most striking outcomes came from two patients who received conditioning—a preparatory treatment to help the engineered cells take hold. One patient's HIV stayed suppressed for nearly a year without their regular medications, and another for nearly two years. For context, most HIV patients need to take daily pills for life to keep the virus under control.

Dr. Mehrdad Abedi, who helped lead the trial at UC Davis, called the depth of viral suppression in these patients "especially compelling." Both patients had started HIV treatment early in their infection—which matters, because early treatment means the virus hasn't had time to establish itself as deeply in the body.

Other Research Teams Are Pursuing Similar Paths

Caring Cross is not alone in this approach. Researchers at other institutions have been testing CAR-T therapy for HIV using slightly different designs. One recent study, published in Nature, tested something called M10 CAR-T cells in 18 patients. These engineered cells were designed with multiple capabilities: they target HIV-infected cells directly, they can neutralize free-floating virus particles, and they're engineered to travel to specific parts of the immune system where HIV hides. The results showed that about 74% of the cell infusions led to significant viral suppression, with viral loads dropping by an average of 67% on average. Over a five-month follow-up period, 10 of those patients showed sustained reductions in the amount of HIV-infected cells.

Other teams are exploring variations on this theme—for example, targeting different parts of the HIV virus, or combining CAR-T cells with other genetic techniques like CRISPR to activate hidden virus and make it vulnerable to the engineered immune cells.

Why This Matters: The Persistent Problem

To understand why this is potentially significant, it helps to know what makes HIV so difficult to treat. The virus integrates itself into the DNA of certain cells—essentially hiding in plain sight. Daily antiretroviral drugs keep the virus suppressed while the immune system can't see it, but the moment you stop taking the pills, the virus comes back.

A functional cure—letting patients live without daily medications while keeping the virus under control—has been a long-sought goal in HIV research. CAR-T therapy offers one possible path. The engineered cells could theoretically patrol the bloodstream indefinitely, spotting and destroying infected cells before they produce new virus.

The conditioning regimen also appears important to success. While the exact details haven't been publicly disclosed, the trial data suggests that preparatory treatment helps the engineered cells establish themselves and persist in the patient's body—much like preparing soil before planting a garden.

Historical Context Worth Keeping in Mind

We have seen this pattern before. When CAR-T therapy first emerged for cancer treatment in the early 2010s, initial results in individual patients were striking but raised as many questions as they answered. It took years of careful testing in larger groups to establish where CAR-T works, when it fails, and how to manage side effects. The same path lies ahead for HIV.

There is reason for cautious optimism here. CAR-T therapies for cancer are now standard treatment for certain types of blood cancer, helping patients who had no other options. The underlying science—engineering immune cells to recognize a specific target—is proven. What remains is understanding whether it works the same way for a persistent viral infection as it does for cancer.

What's Left to Figure Out

Early-stage trials like these generate important proof-of-concept, but larger studies are needed before this becomes a standard treatment. Several technical challenges remain: keeping the engineered cells alive and active long-term, preventing the patient's immune system from rejecting the modified cells, and testing whether the approach works across different patient populations, not just those carefully selected for early trials.

There are also known side effects to watch. CAR-T therapies in cancer patients can trigger cytokine release syndrome—essentially an overactive immune response—and, in rare cases, neurological complications. These may look different in HIV patients than they do in cancer patients.

The convergence of multiple research teams working on CAR-T for HIV suggests the technology has matured enough to take on this problem. The early results reported by Caring Cross and others are encouraging. But they remain early results. What happens over the next few years—whether the suppression holds, whether it works in larger and more diverse patient groups—will determine whether this becomes the functional cure the field has been seeking.